PDCD1 and lung carcinoma: The cell-killing effect has a significant potential to improve the efficacy of NSCLC.[8–10] Nivolumab is a human PD-1 immune checkpoint inhibitor antibody, which can be blocked.[11] Disrupting PD-1 mediated signaling pathway and restoring tumor immunity in lung cancer in recent year.